Andrew Guggenhime
Direttore Finanziario/CFO presso VAXCYTE, INC.
Patrimonio netto: 7 M $ in data 31/05/2023
Profilo
Andrew L.
Guggenhime is currently the Chairman at Caribou Biosciences, Inc. and the President & Chief Financial Officer at Vaxcyte, Inc. He previously worked as the Director at CardioDx, Inc. from 2014 to 2016, Independent Director at Metacrine, Inc. from 2018 to 2023, Assistant VP-Real Estate Capital Markets Group at Wells Fargo & Co., Chief Financial Officer & Senior Vice President at Neoforma, Inc. from 2000 to 2006, Chief Financial Officer at Calistoga Pharmaceuticals, Inc. from 2010 to 2011, Chief Financial Officer & Senior Vice President at Abbott Biotherapeutics Corp.
from 2008 to 2010, Chief Financial Officer & Senior Vice President at PDL BioPharma, Inc. from 2006 to 2008, and Chief Financial Officer at Dermira, Inc. from 2018 to 2020.
He also worked as a Vice President at Merrill Lynch & Co., Inc. from 1996 to 2000.
Mr. Guggenhime completed his undergraduate degree at Middlebury College and holds an MBA from Kellogg School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VAXCYTE, INC.
0.09% | 18/06/2024 | 96 720 ( 0.09% ) | 7 M $ | 31/05/2024 |
METACRINE INC
-.--% | 03/02/2023 | 0 ( -.--% ) | - $ | 31/05/2023 |
| 15/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Andrew Guggenhime
| Società | Posizione | Inizio |
|---|---|---|
| VAXCYTE, INC. | Direttore Finanziario/CFO | 01/05/2020 |
| CARIBOU BIOSCIENCES, INC. | Presidente | - |
Precedenti posizioni note di Andrew Guggenhime
| Società | Posizione | Fine |
|---|---|---|
| METACRINE, INC. | Direttore/Membro del Consiglio | 23/03/2023 |
| DERMIRA, INC. | Direttore Finanziario/CFO | 01/05/2020 |
| CARDIODX INC | Direttore Finanziario/CFO | 28/04/2014 |
Calistoga Pharmaceuticals, Inc.
 Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Direttore Finanziario/CFO | 01/04/2011 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Direttore Finanziario/CFO | 01/06/2010 |
Formazione di Andrew Guggenhime
| Middlebury College | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| WELLS FARGO & COMPANY | Finance |
| METACRINE, INC. | Health Technology |
| VAXCYTE, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Aziende private | 7 |
|---|---|
Neoforma, Inc.
 Neoforma, Inc. Medical DistributorsDistribution Services Neoforma, Inc. provides e-commerce services to healthcare industry. It also provides supply chain management solutions between hospitals and suppliers. The Company was founded in 1996 and is located in SanJose, CA. | Distribution Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
Calistoga Pharmaceuticals, Inc.
Calistoga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA. | Health Technology |
CardioDx, Inc.
 CardioDx, Inc. Medical/Nursing ServicesHealth Services CardioDx, Inc. operates as a cardiovascular genomic diagnostics firm. It develops proprietary tests that improve treatment decisions and patient outcomes on coronary artery disease, cardiac arrhythmia, and heart failure. The company was founded by David L. Levison and Christopher R. Burrow in 2004 and is headquartered in Redwood, CA. | Health Services |
| Merrill Lynch & Co., Inc. | Finance |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
- Borsa valori
- Insiders
- Andrew Guggenhime
